The long awaited TransCon PTH phase 3 will start soon!
TransCon PTH is an investigational long-acting prodrug in development as a potential once-daily replacement therapy for hypoparathyroidism. By providing PTH at physiologic levels for 24 hours a day, TransCon PTH is designed to normalize blood and urinary calcium levels, serum phosphate levels and bone turnover thus addressing both the short-term symptoms and long-term complications of hypoparathyroidism.
Ascendis Pharma has finished phase 1 with positive results, and now are completing phase 2. By the start of next year, they will be ready to start phase 3 which will involve many more patients with hypoparathyroidism who would like to participate. Please stay tuned to either our website or the Ascendis Pharma website for more information.